• Explore /
  • Poster
  • / The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

Abstract Video & Slides Poster

Authors

Andrew Armstrong

Andrew J. Armstrong

Duke Cancer Institute Center for Prostate & Urologic Cancers, Duke University, Durham, NC

Andrew J. Armstrong , Michael S. Gordon , Melissa Andrea Reimers , Alex Sedkov , Kate Lipford , Juliana Snavely-Merhaut , Sonia Kumar , Sylvie Mireille Guichard , Neal Shore

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer– Advanced/Castrate-Resistant

Clinical Trial Registration Number

NCT04575766

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS5085)

DOI

10.1200/JCO.2021.39.15_suppl.TPS5085

Abstract #

TPS5085

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

Poster

2013 Genitourinary Cancers Symposium

Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.

Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.

First Author: Mark T. Fleming

First Author: Ronan Le Moigne

First Author: Pier VItale Nuzzo

First Author: Xiaolin Zhu